Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?
QIAGEN cuts its 2026 growth outlook after a Q1 miss, but margins, cash flow and a debt-free balance sheet could steady the narrative.
QGEN targets steadier growth through 2027, leaning on new launches, Connect automation and QIAstat-Dx menu expansion amid choppy demand.
QGEN's new QIA Agent platform uses conversational AI to streamline experiment planning and ordering support.
Qiagen N.V. (QGEN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Examine Qiagen's (QGEN) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Qiagen N.V. (QGEN) Discusses Strategic Priorities and Latest Developments for QuantiFERON and Latent Tuberculosis Testing Transcript
Qiagen (QGEN) came out with quarterly earnings of $0.54 per share, missing the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $0.58 per share a year ago.
While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Qiagen N.V. (QGEN) Q1 2026 Earnings Call Transcript
Bridgefront Capital LLC bought a new position in shares of Qiagen N.V. (NYSE: QGEN) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 13,650 shares of the company's stock, valued at approximately $610,000. Several other hedge funds and other
Qiagen N.V. (QGEN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript